 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--Regulatory News: NANOBIOTIX Euronext : NANO NASDAQ: NBTX the Company, a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. PharmaEngine to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously disclosed i 